Dirithromycin is a macrolide antibiotic prodrug converted in vivo to erythromycylamine, active against respiratory tract pathogens and offering once-daily dosing; it is largely withdrawn from markets but retained for residual compendial and comparative analytical needs. Simson Pharma's Dirithromycin reference standard supports these legacy applications.

Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Dirithromycin Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.